Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

Icahn School of Medicine at Mount Sinai401 enrolled

Overview

The purpose of the research is to determine whether repairing a tricuspid valve (TV) in patients with mild to moderate tricuspid regurgitation (TR), at the time of planned mitral valve surgery (MVS), would improve the heart health of those who receive it compared to those who do not. At this point, the medical community is split in their opinion on whether surgeons should routinely repair mild to moderate TR in patients who are undergoing planned mitral valve surgery, and this study will answer this question.

The tricuspid valve controls the flow of blood in your heart between the right ventricle and the right atrium. TR is a condition where the valve does not close fully when it is supposed to and blood can then leak back into the right atrium. When TR becomes severe, surgery is usually performed to correct it. The purpose of the research is to determine whether repairing a tricuspid valve in patients with mild to moderate TR, at the time of planned mitral valve surgery, would improve the heart health of those who receive it compared to those who do not. There are no new or "experimental" procedures being tested in this study: both the mitral valve procedure and the tricuspid valve repair procedure are well established surgeries and are regularly performed together in patients who have severe TR. The available evidence addressing this issue is not definite: it is based on less rigorous methods of investigation, and the results have been conflicting. The study being proposed here will use rigorous scientific methods and should result in a very high level of certainty about what surgical treatment is best for patients with your condition. This study will enroll people scheduled for mitral valve surgery with mild to moderate tricuspid regurgitation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Undergoing MVS for degenerative MR\* with (a) Moderate TR as determined by transthoracic 2D echocardiography, or (b) Tricuspid annular dimension ≥ 40 mm (index: ≥21mm/M2 BSA) and none/trace or mild TR, determined by echocardiography. * Age ≥ 18 years * Able to sign Informed Consent and Release of Medical Information forms * "Degenerative mitral valve disease refers to a spectrum of conditions in which morphologic changes in the connective tissues of the mitral valve cause structural lesions . . ., such as chordal elongation, chordal rupture, leaflet tissue expansion, and annular dilation typically resulting in mitral regurgitation due to leaflet prolapse." This definition excludes rheumatic heart disease. (Anyanwu AC, Adams DH. (2007) Etiological classification of degenerative mitral valve disease: Barlow's disease and fibroelasticity deficiency. Semin Thorac Cardiovasc Surg; 19(2): 90-6). Exclusion Criteria: * Functional MR * Evidence of sub-optimal fluid management (e.g., lack of diuretics, weight in excess of dry weight) in the opinion of the cardiology investigator * Structural / organic TV disease * Severe TV regurgitation as determined by preoperative transthoracic echocardiography (TTE) * Implanted pacemaker or defibrillator, where the leads cross the TV from the right atrium into the right ventricle * Concomitant cardiac surgery other than atrial fibrillation correction surgery (PVI, Maze, LAA closure), closure of PFO or ASD, or CABG * Cardiogenic shock at the time of randomization * STEMI requiring intervention within 7 days prior to randomization * Evidence of cirrhosis or hepatic synthetic failure * Severe, irreversible pulmonary hypertension in the judgment of the investigator * Pregnancy at the time of randomization * Therapy with an investigational intervention at the time of screening, or plan to enroll patient in additional investigational intervention study during participation in this trial * Any concurrent disease with life expectancy \< 2 years * Unable or unwilling to provide informed consent * Unable or unwilling to comply with study follow up in the opinion of the investigator

Locations (41)

University of Southern California

Los Angeles, California, United States

Stanford University School of Medicine

Stanford, California, United States

Yale University School of Medicine - Yale-New Haven Hospital

New Haven, Connecticut, United States

Emory University

Atlanta, Georgia, United States

University of Maryland

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Percentage of Participants With Treatment Failure

The primary outcome of this trial is treatment failure defined as the composite of (1) death from any cause, (2) reoperation for TR, (3) presence of severe TR at two years post randomization or, for patients enrolled with less than moderate TR and annular dilatation, progression by two grades (i.e., from none/trace TR to moderate TR) at two years post randomization.

Time frame: 24 Months

Secondary Outcomes

Number of Participants With Major Adverse Cardiac and Cerebrovascular Events (MACCE)

Major Adverse Cardiac and Cerebrovascular Events (MACCE) is defined as a non-weighted composite score comprised of the following components: Death, Stroke, and Serious heart failure events

Time frame: up to 24 Months

Number of Participants With NYHA Classification I-IV

Functional status will be assessed by the New York Heart Association (NYHA) Classification scale which ranges from 1 (no physical limitations) to 4 (severe limitation of physical activity). 1. Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. 2. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. 3. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest. 4. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. 5. No NYHA class listed or unable to determine

Time frame: at 24 Months

Diuretic Use

The diuretic requirements of patients will be assessed.

Time frame: 24 Months

Six Minute Walk Test

The total distance, in feet, walked in six minutes

Time frame: 24 Months

Number of Participants With Degree of TR

Degree of TR assessed by echocardiography, categorized according to American Society of Echocardiography guidelines as none/mild/moderate/severe.

Time frame: up to 24 Months

Right Ventricular Size

Time frame: 24 Months

Number of Participants With Normal RV Function

Number of Participants with Normal RV Function assessed by echocardiography.

Time frame: up to 24 Months

Peak Tricuspid Annular Velocity

Time frame: 24 Months

Tricuspid Annular Peak Systolic Excursion (TAPSE)

Degree of RV function assessed by TAPSE

Time frame: 24 Months

Right Ventricular Fractional Area Change (RVFAC)

Degree of RV function assessed by RVFAC

Time frame: 24 Months

Pulmonary Artery Pressure

Pulmonary artery pressure assessed by echocardiography.

Time frame: up to 24 Months

Right Ventricular Volume

RV Volume as measured by transthoracic 3D echocardiography.

Time frame: 24 Months

SF-12

Quality of Life assessed by SF-12. A measure of perceived health (health-related quality of life \[QoL\]) that describes the degree of general physical health status and mental health distress. Higher scores indicate higher levels of health. The physical and mental health scores on the 12-Item Short Form Survey (SF-12) are reported as T scores (mean, 50±10, 50 indicates the population mean with a standard deviation of 10), with higher scores indicating better health status.

Time frame: 24 Months

Kansas City Cardiomyopathy Questionnaire (KCCQ)

Quality of Life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ). KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life, in which higher scores reflect better health status. Scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary range from 0 to 100, with higher scores indicating a better quality of life and fewer symptoms and physical limitations associated with heart failure.

Time frame: 24 Months

EuroQoL (EQ-5D)

Quality of Life assessed by EuroQoL (EQ-5D) - a standardised instrument for use as a measure of health outcome. Scores on the EuroQol (EQ-5D) visual analogue scale range from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate higher levels of health.

Time frame: 24 Months

Survival

Incidence of participants alive

Time frame: up to 60 Months

Length of Index Hospitalization

Time frame: average 30 days

Number of Participants With Readmission

Incidence of readmissions

Time frame: up to 24 months

Number of Participants With TV Reoperations

Number of participants with TV reoperations

Time frame: up to 24 months

Economic Measures (Inpatient Costs)

Inpatient costs will be measured through the collection of hospital billing.

Time frame: up to 60 months

Number of Participants With Serious Adverse Events

Safety as measured by frequency of serious adverse events.

Time frame: 24 months

Gait Speed Test

Frailty will be assessed using the Gait Speed Test, which measures the average speed of three 5 meter walks

Time frame: 24 months

Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

Overview

Conditions

Interventions

Eligibility

Locations (41)

Outcomes

Primary Outcomes

Secondary Outcomes